The road to accurate specimen collection starts with Puritan
 

GenoType® MTBDRsl Now Available

From Hain Life Sciences, GenoType® MTBDRsl is a molecular genetic assay which allows the simultaneous detection of the M.tuberculosis complex and its Resistance to Fluoroquinolones and/or Aminoglycosides/Cyclic Peptides and/or Ethambutol from smear-positive pulmonary clinical specimens or cultivated samples.

In combination with the GenoType® MTBDRplus the assay allows the detection of XDR-TB-cases.

The GenoType® MTBDRsl is based on the DNA STRIP® technology and permits the simultaneous molecular genetic identification of
  • the M. tuberculosis complex

  • its resistance to fluoroquinolones like ofloxacin and moxifloxacin by the detection of the most common mutations in the gyrA gene

  • its resistance to the injectable antibiotics (viomycin, kanamycin, amikacin and capreomycin) by detection of the most common mutations in the rrs gene

  • its resistance to the first-line drug ethambutol, by detection of the most common mutations in the embB gene

from smear-positive pulmonary clinical specimens or cultivated samples.


Indications for the use of GenoType® MTBDRsl
Diagnosing patients
  • with MDR-TB to receive information on further antibiotic resistances

  • after therapy failure and relapse

  • from countries with high usage of the respective drugs

  • in high burden MDR-/XDR-TB regions

Benefits and advantages of using GenoType® MTBDRsl
  • Detection of XDR-TB in patients previously diagnosed with an MDR-TB by testing with the GenoType® MTBDRplus.

  • Confirmation of DST results.

  • Minimizing extreme side effects through an appropriate therapy scheme.

  • Highly economic as expensive, ineffective drugs can be avoided.


NOTE: This item is from our 'historic' database and may contain information which is not up to date.

Source : Hain Lifescience GmbH View Company Information

Posted on March 10, 2009